Literature DB >> 27687905

Impact of gender on safety and efficacy of Rivaroxaban in adolescents & young adults with venous thromboembolism.

Manuela Krause1, Anna Henningsen2, Antje Torge2, David Juhl3, Ralf Junker4, Gili Kenet5, Dorothee Kowalski2, Verena Limperger4, Rolf Mesters6, Angela Rocke4, Maria Shneyder7, Hartmut Clausnizer2, Hanna Schiesewitz2, Ulrike Nowak-Göttl8.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27687905     DOI： 10.1016/j.thromres.2016.09.007

Source DB:  PubMed          Journal:  Thromb Res        ISSN： 0049-3848            Impact factor:   3.944


× No keyword cloud information.
  2 in total

1.  Heavy menstrual bleeding in women on anticoagulant treatment for venous thromboembolism: Comparison of high- and low-dose rivaroxaban with aspirin.

Authors:  Kochawan Boonyawat; Anthonie W A Lensing; Martin H Prins; Jan Beyer-Westendorf; Paolo Prandoni; Ida Martinelli; Saskia Middeldorp; Akos F Pap; Jeffrey I Weitz; Mark Crowther
Journal:  Res Pract Thromb Haemost       Date:  2021-02-17

2.  Do women with venous thromboembolism bleed more than men during anticoagulation? Data from the real-life, prospective START-Register.

Authors:  Gualtiero Palareti; Cristina Legnani; Emilia Antonucci; Benilde Cosmi; Anna Falanga; Daniela Poli; Daniela Mastroiacovo; Vittorio Pengo; Walter Ageno; Sophie Testa
Journal:  Ther Adv Drug Saf       Date:  2021-12-16
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.